Upgrade to SI Premium - Free Trial

Vertex Pharma (VRTX) Tops Q2 EPS by 19c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus

July 31, 2019 4:04 PM
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $1.26, $0.19 better than the analyst estimate of $1.07. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Earnings Guidance Hot Guidance Management Comments

Next Articles